72.33
-0.01 (-0.01%)
| Previous Close | 72.34 |
| Open | 72.35 |
| Volume | 1,973,375 |
| Avg. Volume (3M) | 2,210,042 |
| Market Cap | 11,948,339,200 |
| Price / Earnings (Forward) | 90.91 |
| Price / Sales | 12.07 |
| Price / Book | 24.04 |
| 52 Weeks Range | |
| Earnings Date | 6 May 2026 |
| Profit Margin | -63.86% |
| Operating Margin (TTM) | -111.59% |
| Diluted EPS (TTM) | -2.99 |
| Quarterly Revenue Growth (YOY) | 10.10% |
| Total Debt/Equity (MRQ) | 413.80% |
| Current Ratio (MRQ) | 9.66 |
| Operating Cash Flow (TTM) | -501.78 M |
| Levered Free Cash Flow (TTM) | -368.16 M |
| Return on Assets (TTM) | -10.59% |
| Return on Equity (TTM) | -118.62% |
Market Trend
| Short Term | Medium Term | ||
| Industry | Biotechnology (US) | Bullish | Mixed |
| Biotechnology (Global) | Bullish | Mixed | |
| Stock | Ionis Pharmaceuticals, Inc. | Bullish | Bullish |
AIStockmoo Score
| Analyst Consensus | 4.0 |
| Insider Activity | -3.5 |
| Price Volatility | 2.0 |
| Technical Moving Averages | 1.0 |
| Technical Oscillators | -0.5 |
| Average | 0.60 |
|
Ionis Pharmaceuticals is the leading developer of antisense technology to discover and develop novel drugs. Its broad clinical and preclinical pipeline targets a wide variety of diseases, with an emphasis on cardiovascular, metabolic, neurological, and rare diseases. Ionis and Biogen brought Spinraza to market in 2016 as a treatment for spinal muscular atrophy, and Biogen launched ALS drug Qalsody in 2023. Ionis brought two additional drugs to market via its cardiovascular-focused subsidiary Akcea, including ATTR amyloidosis drug Tegsedi (2018) and cardiology drug Waylivra (Europe, 2019). Ionis and AstraZeneca launched polyneuropathy drug Wainua in 2024. Ionis received FDA approval in 2024 for Tryngolza for a rare high-triglyceride syndrome, marking its first independent launch. |
|
| Sector | Healthcare |
| Industry | Biotechnology |
| Investment Style | Small Core |
| % Held by Insiders | 0.83% |
| % Held by Institutions | 108.17% |
Ownership
| Name | Date | Shares Held |
|---|---|---|
| Tweedy, Browne Co Llc | 31 Dec 2025 | 2,464,930 |
| 52 Weeks Range | ||
| Price Target Range | ||
| High | 104.00 (Leerink Partners, 43.79%) | Buy |
| Median | 100.00 (38.26%) | |
| Low | 77.00 (Stifel, 6.46%) | Hold |
| Average | 96.80 (33.83%) | |
| Total | 4 Buy, 1 Hold | |
| Avg. Price @ Call | 79.91 | |
| Firm | Date | Target Price | Call | Price @ Call |
|---|---|---|---|---|
| Leerink Partners | 03 Mar 2026 | 104.00 (43.79%) | Buy | 78.66 |
| Piper Sandler | 27 Feb 2026 | 100.00 (38.26%) | Buy | 81.15 |
| 06 Feb 2026 | 87.00 (20.28%) | Buy | 86.50 | |
| Needham | 26 Feb 2026 | 103.00 (42.40%) | Buy | 80.60 |
| Stifel | 26 Feb 2026 | 77.00 (6.46%) | Hold | 80.60 |
| Wells Fargo | 05 Jan 2026 | 100.00 (38.26%) | Buy | 78.53 |
| Name | Avg. Buy ($) | Avg. Sell ($) | Net Quantity | Net Value ($) |
|---|---|---|---|---|
| JENNE KYLE | - | 75.66 | -37,277 | -2,820,378 |
| MONIA BRETT P | - | 75.51 | -160,773 | -12,126,084 |
| O'NEIL PATRICK R. | - | 75.36 | -10,148 | -764,753 |
| Aggregate Net Quantity | -208,198 | |||
| Aggregate Net Value ($) | -15,711,215 | |||
| Aggregate Avg. Buy ($) | - | |||
| Aggregate Avg. Sell ($) | 75.51 | |||
| Name | Holder | Date | Type | Quantity | Price | Value ($) |
|---|---|---|---|---|---|---|
| JENNE KYLE | Officer | 10 Mar 2026 | Automatic sell (-) | 37,277 | 75.66 | 2,820,378 |
| JENNE KYLE | Officer | 10 Mar 2026 | Option execute | 37,277 | - | - |
| MONIA BRETT P | Officer | 10 Mar 2026 | Automatic sell (-) | 34,103 | 75.66 | 2,580,233 |
| MONIA BRETT P | Officer | 10 Mar 2026 | Option execute | 34,103 | - | - |
| MONIA BRETT P | Officer | 09 Mar 2026 | Automatic sell (-) | 126,670 | 75.36 | 9,545,851 |
| MONIA BRETT P | Officer | 09 Mar 2026 | Option execute | 114,351 | - | - |
| O'NEIL PATRICK R. | Officer | 09 Mar 2026 | Automatic sell (-) | 10,148 | 75.36 | 764,753 |
| Date | Type | Details |
|---|---|---|
| 21 Jan 2026 | Announcement | DAWNZERA™ (donidalorsen) approved in the European Union for hereditary angioedema (HAE) |
| 12 Jan 2026 | Announcement | Ionis well-positioned for continued momentum and substantial value creation in 2026 with two new independent launches and several pivotal data readouts |
| 07 Jan 2026 | Announcement | Ionis partner GSK announces positive topline results from B-Well 1 and B-Well 2 Phase 3 studies for bepirovirsen, a potential first-in-class medicine for chronic hepatitis B |
| 06 Jan 2026 | Announcement | Ionis to present at 44th Annual J.P. Morgan Healthcare Conference |
The support, resistance and trendline levels presented has been generated by an artificial intelligence (AI) model and should be interpreted with caution.
Portfolio
| Realized Profit | - |
| Unrealized Profit | - |
| Dividend Received 2026 | - |
| Total Profit | - |
| Avg. Return | - |
| Quantity (Buy) | - |
| Avg. Price (Buy) | - |
| Quantity (Sold) | - |
| Avg. Price (Sold) | - |